Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2/glutamine pathway.
Gemcitabine
Deoxycytidine
/ analogs & derivatives
Animals
Cholangiocarcinoma
/ drug therapy
Humans
Curcumin
/ pharmacology
Drug Synergism
Drug Resistance, Neoplasm
/ drug effects
Mice
Glutamine
/ metabolism
Cell Line, Tumor
Apoptosis
/ drug effects
Cell Proliferation
/ drug effects
Xenograft Model Antitumor Assays
Signal Transduction
/ drug effects
Bile Duct Neoplasms
/ drug therapy
Glutaminase
/ metabolism
Male
SLC7A8 (LAT2)
Cholangiocarcinoma
Curcumin
Drug resistance
Gemcitabine
Glutamine
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 Jul 2024
11 Jul 2024
Historique:
received:
25
11
2023
accepted:
05
07
2024
medline:
12
7
2024
pubmed:
12
7
2024
entrez:
11
7
2024
Statut:
epublish
Résumé
Cholangiocarcinoma (CCA) is often diagnosed late, leading to incomplete tumor removal, drug resistance and reduced chemotherapy efficacy. Curcumin has the potential for anti-cancer activity through various therapeutic properties and can improve the efficacy of chemotherapy. We aimed to investigate the synergistic effect of a combination of curcumin and gemcitabine against CCA, targeting the LAT2/glutamine pathway. This combination synergistically suppressed proliferation in gemcitabine-resistant CCA cells (KKU-213B
Identifiants
pubmed: 38992159
doi: 10.1038/s41598-024-66945-7
pii: 10.1038/s41598-024-66945-7
doi:
Substances chimiques
Gemcitabine
0
Deoxycytidine
0W860991D6
Curcumin
IT942ZTH98
Glutamine
0RH81L854J
Glutaminase
EC 3.5.1.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
16059Subventions
Organisme : National Research Council of Thailand
ID : NRCT5-RGJ63003-063
Organisme : National Science Research and Innovation Fund (NSRF)
ID : B05F630053/5856
Informations de copyright
© 2024. The Author(s).
Références
Sarcognato, S. et al. Cholangiocarcinoma. Pathologica. 113, 158–169 (2021).
pubmed: 34294934
pmcid: 8299326
doi: 10.32074/1591-951X-252
Chaiteerakij, R. et al. Characteristics and outcomes of cholangiocarcinoma by region in Thailand: A nationwide study. World J. Gastroenterol. 23, 7160–7167 (2017).
pubmed: 29093624
pmcid: 5656463
doi: 10.3748/wjg.v23.i39.7160
Vaquero, J. et al. Epithelial–mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks. J. Hepatol. 66, 424–441 (2017).
pubmed: 27686679
doi: 10.1016/j.jhep.2016.09.010
Khan, S. A., Tavolari, S. & Brandi, G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int. 39(Suppl 1), 19–31 (2019).
pubmed: 30851228
doi: 10.1111/liv.14095
Sirica, A. E. Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy. Hepatology. 41, 5–15 (2005).
pubmed: 15690474
doi: 10.1002/hep.20537
Wongwattanakul, M. et al. Classification of Gemcitabine resistant Cholangiocarcinoma cell lines using synchrotron FTIR microspectroscopy. J. Biophotonics. 10, 367–376 (2017).
pubmed: 26996159
doi: 10.1002/jbio.201500253
Giordano, A. & Tommonaro, G. Curcumin and cancer. Nutrients. 11 (2019).
Ming, T. et al. Curcumin: An epigenetic regulator and its application in cancer. Biomed. Pharmacother. 156, 113956 (2022).
pubmed: 36411666
doi: 10.1016/j.biopha.2022.113956
Rahmani, A. H., Alsahli, M. A., Aly, S. M., Khan, M. A. & Aldebasi, Y. H. Role of curcumin in disease prevention and treatment. Adv. Biomed. Res. 7, 38 (2018).
pubmed: 29629341
pmcid: 5852989
doi: 10.4103/abr.abr_147_16
Prakobwong, S. et al. Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways. Carcinogenesis. 32, 1372–1380 (2011).
pubmed: 21325634
pmcid: 3165121
doi: 10.1093/carcin/bgr032
Prakobwong, S. et al. Curcumin decreases cholangiocarcinogenesis in hamsters by suppressing inflammation-mediated molecular events related to multistep carcinogenesis. Int. J. Cancer. 129, 88–100 (2011).
pubmed: 20824699
doi: 10.1002/ijc.25656
Yoshida, K., Toden, S., Ravindranathan, P., Han, H. & Goel, A. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression. Carcinogenesis. 38, 1036–1046 (2017).
pubmed: 29048549
pmcid: 5862331
doi: 10.1093/carcin/bgx065
Cho, C. J. et al. The modulation study of multiple drug resistance in bladder cancer by curcumin and resveratrol. Oncol. Lett. 18, 6869–6876 (2019).
pubmed: 31807190
pmcid: 6876334
Fan, W. H., Wang, F. C., Jin, Z., Zhu, L. & Zhang, J. X. Curcumin synergizes with cisplatin to inhibit colon cancer through targeting the microRNA-137-glutaminase axis. Curr. Med. Sci. 42, 108–117 (2022).
pubmed: 34958454
doi: 10.1007/s11596-021-2469-0
Coloff, J. L. et al. Differential glutamate metabolism in proliferating and quiescent mammary epithelial cells. Cell Metab. 23, 867–880 (2016).
pubmed: 27133130
doi: 10.1016/j.cmet.2016.03.016
Wang, Q. & Holst, J. L-type amino acid transport and cancer: Targeting the mTORC1 pathway to inhibit neoplasia. Am. J. Cancer Res. 5, 1281–1294 (2015).
pubmed: 26101697
pmcid: 4473310
El Ansari, R. et al. The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer. Breast Cancer Res. Treat. 181, 1–12 (2020).
pubmed: 32200487
pmcid: 7182634
doi: 10.1007/s10549-020-05586-6
Xiong, G. et al. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer. J. Hematol. Oncol. 12, 97 (2019).
pubmed: 31514732
pmcid: 6739963
doi: 10.1186/s13045-019-0777-7
Kim, G. W. et al. Glutamine synthetase as a therapeutic target for cancer treatment. Int. J. Mol. Sci. 22 (2021).
Wattanawongdon, W. et al. Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. Int. J. Oncol. 47, 398–410 (2015).
pubmed: 25998688
doi: 10.3892/ijo.2015.3019
Yang, Y., Li, J., Yao, L. & Wu, L. Effect of photodynamic therapy on gemcitabine-resistant cholangiocarcinoma in vitro and in vivo through KLF10 and EGFR. Front. Cell Dev. Biol. 9, 710721 (2021).
pubmed: 34805140
pmcid: 8595284
doi: 10.3389/fcell.2021.710721
Kunnumakkara, A. B. et al. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappa B-regulated gene products. Cancer Res. 67, 3853–3861 (2007).
pubmed: 17440100
doi: 10.1158/0008-5472.CAN-06-4257
Liu, P. et al. Curcumin enhances anti-cancer efficacy of either gemcitabine or docetaxel on pancreatic cancer cells. Oncol. Rep. 44, 1393–1402 (2020).
pubmed: 32945513
pmcid: 7448442
Hu, A. et al. Curcumin induces G2/M cell cycle arrest and apoptosis of head and neck squamous cell carcinoma in vitro and in vivo through ATM/Chk2/p53-dependent pathway. Oncotarget. 8, 50747–50760 (2017).
pubmed: 28881600
pmcid: 5584201
doi: 10.18632/oncotarget.17096
Weir, N. M. et al. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol. Ther. 6, 178–184 (2007).
pubmed: 17218783
doi: 10.4161/cbt.6.2.3577
Chen, M. et al. Curcumin analog WZ26 induces ROS and cell death via inhibition of STAT3 in cholangiocarcinoma. Cancer Biol. Ther. 24, 2162807 (2023).
pubmed: 36647192
pmcid: 9851268
doi: 10.1080/15384047.2022.2162807
Kahya, U., Koseer, A. S. & Dubrovska, A. Amino acid transporters on the guard of cell genome and epigenome. Cancers (Basel). 13 (2021).
Feng, M. et al. LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. J. Exp. Clin. Cancer Res. 37, 274 (2018).
pubmed: 30419950
pmcid: 6233565
doi: 10.1186/s13046-018-0947-4
Hurkmans, E. G. E. et al. SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin. Front. Pharmacol. 13, 1042989 (2022).
pubmed: 36438828
pmcid: 9681801
doi: 10.3389/fphar.2022.1042989
Wang, F. M. et al. SLC7A8 overexpression inhibits the growth and metastasis of lung adenocarcinoma and is correlated with a dismal prognosis. Aging (Albany NY). 16, 1605–1619 (2024).
pubmed: 38244585
pmcid: 10866399
doi: 10.18632/aging.205446
Edemir, B. identification of prognostic organic cation and anion transporters in different cancer entities by in silico analysis. Int. J. Mol. Sci. 21 (2020).
Xu, X. et al. Metabolic reprogramming and epigenetic modifications in cancer: From the impacts and mechanisms to the treatment potential. Exp. Mol. Med. 55, 1357–1370 (2023).
pubmed: 37394582
pmcid: 10394076
doi: 10.1038/s12276-023-01020-1
Dey, P., Kimmelman, A. C. & DePinho, R. A. Metabolic codependencies in the tumor microenvironment. Cancer Discov. 11, 1067–1081 (2021).
pubmed: 33504580
pmcid: 8102306
doi: 10.1158/2159-8290.CD-20-1211
Wang, Z. et al. Targeting glutaminolysis: New perspectives to understand cancer development and novel strategies for potential target therapies. Front. Oncol. 10, 589508 (2020).
pubmed: 33194749
pmcid: 7649373
doi: 10.3389/fonc.2020.589508
Cao, J. et al. Expression of GLS1 in intrahepatic cholangiocarcinoma and its clinical significance. Mol. Med. Rep. 20, 1915–1924 (2019).
pubmed: 31257527
Wang, Y. et al. GLUL promotes cell proliferation in breast cancer. J. Cell Biochem. 118, 2018–2025 (2017).
pubmed: 27791265
doi: 10.1002/jcb.25775
Tardito, S. et al. Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat. Cell Biol. 17, 1556–1568 (2015).
pubmed: 26595383
pmcid: 4663685
doi: 10.1038/ncb3272
Shi, X., Zhang, X., Yi, C., Liu, Y. & He, Q. [(1)(3)N]Ammonia positron emission tomographic/computed tomographic imaging targeting glutamine synthetase expression in prostate cancer. Mol. Imaging. 13 (2014).
Shao, M. et al. Glutamine synthetase-negative hepatocellular carcinoma has better prognosis and response to sorafenib treatment after hepatectomy. Chin. Med. J. (Engl.). 136, 2066–2076 (2023).
pubmed: 37249521
pmcid: 10476731
doi: 10.1097/CM9.0000000000002380
Duan, X., Zhao, T., Wang, J., Wang, J. & Zheng, Y. Curcumol targets glutaminase 1 to regulate glutamine metabolism and induce senescence of hepatic stellate cells. Eur. J. Integr. Med. 62, 102278 (2023).
doi: 10.1016/j.eujim.2023.102278
Ni, R. et al. Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer. Front. Oncol. 13, 1143798 (2023).
pubmed: 36959802
pmcid: 10029103
doi: 10.3389/fonc.2023.1143798
Wang, B., Pei, J., Xu, S., Liu, J. & Yu, J. A glutamine tug-of-war between cancer and immune cells: Recent advances in unraveling the ongoing battle. J. Exp. Clin. Cancer Res. 43, 74 (2024).
pubmed: 38459595
pmcid: 10921613
doi: 10.1186/s13046-024-02994-0
Kawanishi, S., Hiraku, Y., Pinlaor, S. & Ma, N. Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol. Chem. 387, 365–372 (2006).
pubmed: 16606333
doi: 10.1515/BC.2006.049
Yongvanit, P., Pinlaor, S. & Bartsch, H. Oxidative and nitrative DNA damage: key events in opisthorchiasis-induced carcinogenesis. Parasitol. Int. 61, 130–135 (2012).
pubmed: 21704729
doi: 10.1016/j.parint.2011.06.011
Leelawat, K. et al. Prognostic relevance of circulating CK19 mRNA in advanced malignant biliary tract diseases. World J. Gastroenterol. 18, 175–181 (2012).
pubmed: 22253524
pmcid: 3257445
doi: 10.3748/wjg.v18.i2.175
Wang, S. & Zhang, Y. HMGB1 in inflammation and cancer. J. Hematol. Oncol. 13, 116 (2020).
pubmed: 32831115
pmcid: 7443612
doi: 10.1186/s13045-020-00950-x
Zhuo, J. Y. et al. CK19-positive hepatocellular carcinoma is a characteristic subtype. J. Cancer. 11, 5069–5077 (2020).
pubmed: 32742454
pmcid: 7378918
doi: 10.7150/jca.44697
Khoontawad, J. et al. Discovering proteins for chemoprevention and chemotherapy by curcumin in liver fluke infection-induced bile duct cancer. PLoS One. 13, e0207405 (2018).
pubmed: 30440021
pmcid: 6237386
doi: 10.1371/journal.pone.0207405
Jantawong, C. et al. Curcumin-loaded nanocomplexes alleviate the progression of fluke-related cholangiocarcinoma in hamsters. Cancer Nanotechnol. 14, 5 (2023).
doi: 10.1186/s12645-023-00155-0
Sripa, B. et al. Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World J. Gastroenterol. 11, 3392–3397 (2005).
pubmed: 15948244
pmcid: 4315993
doi: 10.3748/wjg.v11.i22.3392
Sripa, B. et al. Functional and genetic characterization of three cell lines derived from a single tumor of an Opisthorchis viverrini-associated cholangiocarcinoma patient. Hum. Cell. 33, 695–708 (2020).
pubmed: 32207095
doi: 10.1007/s13577-020-00334-w
Zheng, S. et al. SynergyFinder plus: Toward better interpretation and annotation of drug combination screening datasets. Genom. Proteom. Bioinform. 20, 587–596 (2022).
doi: 10.1016/j.gpb.2022.01.004
Pinlaor, S. et al. Curcumin reduces oxidative and nitrative DNA damage through balancing of oxidant-antioxidant status in hamsters infected with Opisthorchis viverrini. Mol. Nutr. Food Res. 53, 1316–1328 (2009).
pubmed: 19753608
doi: 10.1002/mnfr.200800567
Paolino, D. et al. Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: Biodistribution, pharmacokinetic features and in vivo antitumor activity. J. Control Release. 144, 144–150 (2010).
pubmed: 20184929
doi: 10.1016/j.jconrel.2010.02.021
Liu, D. et al. Necrosis of cervical carcinoma by dichloroacetate released from electrospun polylactide mats. Biomaterials. 33, 4362–4369 (2012).
pubmed: 22425553
doi: 10.1016/j.biomaterials.2012.02.062
Charoensuk, L. et al. Nanoencapsulated curcumin and praziquantel treatment reduces periductal fibrosis and attenuates bile canalicular abnormalities in Opisthorchis viverrini-infected hamsters. Nanomedicine. 12, 21–32 (2016).
pubmed: 26542278
doi: 10.1016/j.nano.2015.10.005
Thoolen, B. et al. Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary system. Toxicol. Pathol. 38, 5S-81S (2010).
pubmed: 21191096
doi: 10.1177/0192623310386499
Narama, I. et al. A review of nomenclature and diagnostic criteria for proliferative lesions in the liver of rats by a working group of the Japanese Society of Toxicologic Pathology. J. Toxicol. Pathol. 16, 1–17 (2003).
doi: 10.1293/tox.16.1